XNCR

Xencor Inc. (XNCR) | Rumor.io

Xencor

XNCR

Attention (50-day avg)0%

Attention rank (50-day avg)#1,812

Bullish sentiment (50-day avg)95%

Price to earnings ratio-20.7

Market capitalization1.9B

Earnings per share-2.16

Dividend yield (TTM)—

Revenue (annual)125.6M

Net income (annual)-92.1M

Social

What share of all stock conversation is about XNCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Jul 21

Xencor, Inc.'s stock is experiencing strong momentum driven by positive clinical trial developments, particularly for XmAb819 in renal cell carcinoma.
The stock has broken through multiple resistance levels and achieved pattern targets.
Xencor is developing programs targeting autoimmune diseases, including TL1A-related therapies for inflammatory bowel disease (IBD) with XmAb942 and XmAb412.

Generated by AI

Sentiment

Of the messages about XNCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +5.81	89.28% +3.07
Bearish	0%	0%	0% -5.81	10.72% -3.07

Jun 28

$XNCR has a significant partnership with Novartis, with a $150M upfront payment and substantial future potential, despite its market cap only increasing by $100M.
The company's collaboration with Novartis has led to a 32% increase in its stock price, with some investors having tripled their stakes in Q1.
Xencor's recent deal, with $2.41B in mergers and acquisitions across six bispecifics, is seen as very impressive and could lead to further price increases.

Generated by AI

Topics

Of the messages about XNCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	13.33%	69.44%
Technical Analysis	90%	90.91%	66.67%	16.39%
Analysts	10%	9.09%	20%	12.78%
Controversies	0%	0%	0%	0.83%
Earnings	0%	0%	0%	0.28%
Macro	0%	0%	0%	0.28%

Earnings· Feb 27

Xencor, Inc. ($XNCR) beats EPS loss estimates by $0.10 and beats on revenues.
$XNCR reports FQ4 earnings of -25c EPS and $10.94M Revs, missing Estimize Revenue Consensus by $4.33M.
$XNCR beats the Estimize EPS Consensus by 2c and misses the Estimize Revenue Consensus by $4.33M.

Announcements· Oct 4

Xencor, Inc. ($XNCR) has entered into a global collaboration and license agreement with Janssen to advance plamotamab and XmAb CD28 bispecific antibody combinations for the treatment of patients with B-cell malignancies.
The agreement includes a $100M upfront payment, $25M equity investment, and potential milestone payments up to $1.188B, as well as mid-teen to low-twenties % royalties for plamotamab.
Janssen will have exclusive rights to develop and commercialize plamotamab and novel XmAb B-cell targeting bispecific antibodies, with Xencor retaining rights to a second program to be developed together.

Generated by AI

Community

Of the messages about XNCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	15.38%	14.29%	6.35%	15.55%
Newcomers	84.62%	85.71%	93.65%	84.45%

Regulars· Nov 7

$XNCR's XmAb564 showed strong stimulation of Tregs, but may be hindered by "Treg resistance" in inflammatory milieus, potentially impacting therapeutic effectiveness.
Xencor reported GAAP EPS of -$0.55, beating estimates by $0.13, and revenue of $27.3M, exceeding expectations by $6.25M.
XmAb564, Xencor's IL2-Fc Cytokine, demonstrated selective expansion of regulatory T cells in a Phase 1a clinical study, showing promise for future therapeutic applications.

Newcomers· Jun 14

Xencor, Inc. ($XNCR) has been granted a global exclusive license to use the Janssen unit of Johnson & Johnson's ($JNJ) drug plamotamab.
Analysts at Raymond James, BMO Capital, and RBC Capital have all maintained their strong buy or outperform ratings for Xencor, Inc. ($XNCR) despite recent market fluctuations.
Xencor, Inc. ($XNCR) has maintained its position as a strong buy among analysts, with a focus on its clinical-stage biopharmaceutical developments and potential for growth in the market.

Generated by AI

News

BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating

Xencor (XNCR) has an average rating of overweight and mean price target of $31.25, according to anal

8d agoYahoo Finance

Xencor (XNCR) Receives a Buy from Barclays

Detailed price information for Xencor Inc (XNCR-Q) from The Globe and Mail including charting and trades.

18d agoThe Globe and Mail

Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift

20d agoInvesting.com

Xencor to Present at the 2026 Cantor Global Healthcare Conference

PASADENA, Calif., September 02, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will present at the Cantor Global Healthcare Conference on Wednesday, September 9, 2026, at 10:55 a.m. EDT / 7:55 a.m. PDT.

27d agoYahoo Finance

Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating

29d agofinance.yahoo.com

Xencor stock hits 52-week high at 26.18 USD

1mo agoInvesting.com

Also Discussed

Investors talking about XNCR also mention

#	Name	Attention
1	MacroGenics Inc.MGNX	0%+0
2	Chain Bridge ICBRG	0%0
3	Liberty Media Corporation Series A Liberty Formula One Common StockFWONA	0%0
4	Agios Pharmaceuticals, Inc.AGIO	0%0
5	Cellectis S.A. ADRCLLS	0%new
6	EGRX - Eagle Pharmaceuticals, Inc.	——
7	Incyte Corp.INCY	0%new
8	SGEN - Seagen Inc.	——
9	Neurocrine Biosciences, Inc.NBIX	0%new
10	FGEN - FibroGen, Inc.	——

Xencor Inc.

Healthcare
Biotechnology

Xencor Inc. is a clinical-stage biopharmaceutical company focused on designing and developing engineered antibody therapeutics for cancer, autoimmune disorders, and other serious diseases. The company’s XmAb protein engineering platform is used to create next-generation antibodies and bispecific molecules with tailored biological activity, supporting a portfolio of proprietary and partnered programs in clinical development. Xencor’s work centers on protein engineering that can improve how therapies interact with immune targets and disease pathways, making it a specialized participant in modern antibody drug innovation. The company also collaborates with external partners to apply its platform across multiple therapeutic areas, including oncology and immunology. Headquartered in Pasadena, California, Xencor Inc. operates as a biotechnology company whose current business is built around research, development, and collaboration in advanced biologic medicines.

Website

Location

465 North Halstead Street

Pasadena, CA, 91107

United States

Social

What share of all stock conversation is about XNCR?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% 0	0% +0

Jul 21

Xencor, Inc.'s stock is experiencing strong momentum driven by positive clinical trial developments, particularly for XmAb819 in renal cell carcinoma.
The stock has broken through multiple resistance levels and achieved pattern targets.
Xencor is developing programs targeting autoimmune diseases, including TL1A-related therapies for inflammatory bowel disease (IBD) with XmAb942 and XmAb412.

Generated by AI

Sentiment

Of the messages about XNCR that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	100%	100%	100% +5.81	89.28% +3.07
Bearish	0%	0%	0% -5.81	10.72% -3.07

Jun 28

$XNCR has a significant partnership with Novartis, with a $150M upfront payment and substantial future potential, despite its market cap only increasing by $100M.
The company's collaboration with Novartis has led to a 32% increase in its stock price, with some investors having tripled their stakes in Q1.
Xencor's recent deal, with $2.41B in mergers and acquisitions across six bispecifics, is seen as very impressive and could lead to further price increases.

Generated by AI

Topics

Of the messages about XNCR that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	0%	0%	13.33%	69.44%
Technical Analysis	90%	90.91%	66.67%	16.39%
Analysts	10%	9.09%	20%	12.78%
Controversies	0%	0%	0%	0.83%
Earnings	0%	0%	0%	0.28%
Macro	0%	0%	0%	0.28%

Earnings· Feb 27

Xencor, Inc. ($XNCR) beats EPS loss estimates by $0.10 and beats on revenues.
$XNCR reports FQ4 earnings of -25c EPS and $10.94M Revs, missing Estimize Revenue Consensus by $4.33M.
$XNCR beats the Estimize EPS Consensus by 2c and misses the Estimize Revenue Consensus by $4.33M.

Announcements· Oct 4

Xencor, Inc. ($XNCR) has entered into a global collaboration and license agreement with Janssen to advance plamotamab and XmAb CD28 bispecific antibody combinations for the treatment of patients with B-cell malignancies.
The agreement includes a $100M upfront payment, $25M equity investment, and potential milestone payments up to $1.188B, as well as mid-teen to low-twenties % royalties for plamotamab.
Janssen will have exclusive rights to develop and commercialize plamotamab and novel XmAb B-cell targeting bispecific antibodies, with Xencor retaining rights to a second program to be developed together.

Generated by AI

Community

Of the messages about XNCR, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	15.38%	14.29%	6.35%	15.55%
Newcomers	84.62%	85.71%	93.65%	84.45%

Regulars· Nov 7

$XNCR's XmAb564 showed strong stimulation of Tregs, but may be hindered by "Treg resistance" in inflammatory milieus, potentially impacting therapeutic effectiveness.
Xencor reported GAAP EPS of -$0.55, beating estimates by $0.13, and revenue of $27.3M, exceeding expectations by $6.25M.
XmAb564, Xencor's IL2-Fc Cytokine, demonstrated selective expansion of regulatory T cells in a Phase 1a clinical study, showing promise for future therapeutic applications.

Newcomers· Jun 14

Xencor, Inc. ($XNCR) has been granted a global exclusive license to use the Janssen unit of Johnson & Johnson's ($JNJ) drug plamotamab.
Analysts at Raymond James, BMO Capital, and RBC Capital have all maintained their strong buy or outperform ratings for Xencor, Inc. ($XNCR) despite recent market fluctuations.
Xencor, Inc. ($XNCR) has maintained its position as a strong buy among analysts, with a focus on its clinical-stage biopharmaceutical developments and potential for growth in the market.

Generated by AI

Xencor

Social

Jul 21

Jun 28

Earnings· Feb 27

Announcements· Oct 4

Regulars· Nov 7

Newcomers· Jun 14

BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating

Xencor (XNCR) Receives a Buy from Barclays

Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift

Xencor to Present at the 2026 Cantor Global Healthcare Conference

Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating

Xencor stock hits 52-week high at 26.18 USD

Also Discussed

Xencor Inc.

Company Information

Location

BofA Adjusts Price Target on Xencor to $26 From $20, Keeps Neutral Rating

Xencor (XNCR) Receives a Buy from Barclays

Xencor at 12th Annual Cantor Fitzgerald Global Healthcare Conference: late-stage shift

Xencor to Present at the 2026 Cantor Global Healthcare Conference

Raymond James Adjusts Xencor Price Target to $46 From $40, Maintains Strong Buy Rating

Xencor stock hits 52-week high at 26.18 USD

Also Discussed

Social

Jul 21

Jun 28

Earnings· Feb 27

Announcements· Oct 4

Regulars· Nov 7

Newcomers· Jun 14